glp 1 obesity The Unstoppable Rise of GLP-1 Agonists: Revolutionising Diabetes and Treatment Frontiers | GLP−1 receptor agonists

Your body's doing a lot of work right now

University of Miami and Columbia University researchers followed roughly 2,500 New Yorkers for 10 years

The study looked back on their health records for up to three years, beginning when they started taking either a GLP-1 receptor agonistmost commonly semaglutide, liraglutide, or dulaglutideor another type of medication, called an SGLT2 inhibitor, to treat their diabetes

doi: 10.1016/j.humimm.2021.03.004 25 LiuYWuMXuBKangL

Wang ZJ, Han WN, Chai SF, Li Y, Fu CJ, Wang CF, Cai HY, Li XY, Wang X, Hlscher C, Wu MN (2024) Semaglutide promotes the transition of microglia from M1 to M2 type to reduce brain inflammation in APP/PS1/tau mice

This guide is designed to empower you with knowledge, ensuring your path to better health is both effective and safe